Tranzyme Pharma to Speak at Piper Jaffray Healthcare Conference

Tranzyme Pharma to Speak at Piper Jaffray Healthcare Conference

Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and
CEO, will speak at the 24^th Annual Piper Jaffray Healthcare Conference taking
place at the New York Palace hotel, New York, NY November 27-28, 2012.
Tranzyme's session is scheduled for Wednesday, November 28^th at 12:30 pm ET.

A live audio webcast of the presentation will be available in the "Investors"
section of the Tranzyme Pharma website,

About Tranzyme Pharma

Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing novel, mechanism-based
therapeutics for the treatment of upper gastrointestinal (GI) motility
disorders. While approximately 40 percent of people in the U.S. are affected
by these persistent and recurring conditions which disrupt the normal movement
of food throughout the GI tract, there are a limited number of safe and
effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin
agonist for treating the symptoms associated with chronic upper GI motility
disorders. Tranzyme is currently enrolling patients in a Phase 2b trial
(DIGEST) evaluating TZP-102 given prior to meals in diabetic patients with
gastroparesis; top-line data are expected in the first half of 2013. By
leveraging its proprietary drug discovery technology, MATCH™, Tranzyme is
committed to pursuing first-in-class medicines to address areas of significant
unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web
site at

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
Press spacebar to pause and continue. Press esc to stop.